Improve the Service, Double the Retained Profit, Medify Solutions Limited Announces

Toronto (ots/PRNewswire) - Medify Solutions Limited todayannounces its own in-house product for roll out to the NHS.

This new capability will replace the legacy generic solutionprovided for Medify by Pervasic and specifically focuses on the knownrequirements of Healthcare professionals and the global delivery ofMedifyRemote.

The development has been led by the company's NHS team workingwith Medify's live projects to deliver and meet the needs andexpectations of Medify's healthcare clients and the patient.

This investment has been planned by the board of Medify to ensuretotal and complete ownership of not only the customer proposition,but also the complete IPR for all Medify applications. Furthermore,it will significantly contribute to Medify's ability to fulfil itsservice provider status for clients globally, enabling the coredelivery of contractual services to be managed in house by Medifyimmediately removing third party costs.

Jonathan Bryant, Executive Chairman, said: "This development hasbeen completed ahead of schedule and I am delighted, as are ourcustomers, with the new MedifyRemote application approach. Not onlydoes this provide product and corporate ownership to the company andits shareholders, but in a single move increases our revenue andprofit margins two fold. Long-term objectives been achieved and shortterm commercial rewards have been exceeded. The team, led by newGroup CEO Ian O'Reilly, will accelerate a more commerciallyprofitable era for the company and the move into a total solutionsand service provider status with our governmental and corporateclients."

This news release contains forward-looking statements that aresubject to certain risks and uncertainties that may cause actualresults to differ materially from those projected on the basis ofsuch forward-looking statements. The words "estimate," "project,""intends," "expects," "believes," and similar expressions areintended to identify forward-looking statements. Such forward-lookingstatements are made based on management's beliefs, as well asassumptions made by, and information currently available to,management pursuant to the "safe-harbour" provisions of the PrivateSecurities Litigation Reform Act of 1995. For a more completedescription of these and other risk factors that may affect thefuture performance of Medify Solutions Limited, see "Risk Factors" inthe Company's Annual Report on Form 10-KSB and its other filings withthe Securities and Exchange Commission. Readers are cautioned not toplace undue reliance on these forward-looking statements, which speakonly as of the date made and the Company undertakes no obligation todisclose any revision to these forward-looking statements to reflectevents or circumstances after the date made or to reflect theoccurrence of unanticipated events.

ots Originaltext: Medify Solutions LimitedIm Internet recherchierbar: http://www.presseportal.de

Contact:For further information: Medify Press Office: press@medifysolutions.com

Medify Solutions Limited

Zurück zur Übersiche Medizin-Nachrichten

Preisvergleich Medikamente
Medikament oder PZN:   
In Zusammenarbeit mit Medizinfuchs


Improve the Service, Double the Retained Profit, Medify Solutions Limited Announces